Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Metastatic castrate resistant prostate cancer (mCRPC) continues to have poor survival rates due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of novel immunotherapies with demonstrated success in haematological malignancies and melanoma. BiTEs developed for tumour associated antigens in prostate cancer have entered clinical testing. These trials have been hampered by high rates of treatment related adverse events, minimal or transient anti-tumour efficacy and generation of high titres of anti-drug antibodies. This paper aims to analyse the challenges faced by the different BiTE therapy constructs and the mCRPC tumour microenvironment that result in therapeutic resistance and identify possible strategies to overcome these issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By simultaneously binding to a tumor-associated antigen (TAA) on cancer cells and CD3 on T cells, BiTEs force an immunological synapse that facilitates T-cell activation, directed release of cytotoxic granules and cytokines, and ultimately targeted tumor cell lysis.”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In prostate cancer, PSMA is the most frequently targeted TAA due to its abundant expression on malignant cells, but other targets are currently being explored as well [26].”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“…with reduced metastatic burden, and has acted as an important proof of concept for immunotherapies outside of ICIs in prostate cancer treatment, sipuleucal-T has failed to be incorporated into routine treatment for mCRPC due to doubts about limited clinical bene fi t (Kantoff et al., 2010).”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“…(mCRPC) with ARSis, a broader range of chemotherapy agents, and Radium-223 radionucleotide treatment (Petrylak et al., 2004; de Bono et al., 2011; Parker et al., 2013; Beer et al., 2014; James et al., 2016; Fizazi et al., 2017; Kyriakopoulos et al., 2018; Armstrong et al., 2019; Chi et al.,…”
BackgroundEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · cited 1×
“…a broader range of chemotherapy agents, and Radium-223 radionucleotide treatment (Petrylak et al., 2004; de Bono et al., 2011; Parker et al., 2013; Beer et al., 2014; James et al., 2016; Fizazi et al., 2017; Kyriakopoulos et al., 2018; Armstrong et al., 2019; Chi et al., 2019; Fizazi et al.,…”
BackgroundLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Research works printed but not linked: 6
- 2010, Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection - guidelines for Industry
- Agency, 2017, Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins
- 2017, Aptevo therapeutics and MorphoSys end joint development and - commercialization agreement for mor209/es414
- 2022, Harpoon therapeutics reports fourth quarter and full year 2021 financial results and provides corporate update<harpoon-therapeutics-reports-fourth-quarter-and.pdf>
- 2019, Study with bispecific antibody engaging T-cells
- 2023, An interactive website for SEER cancer statistics: surveillance Research Program
Cited by
Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17071064 · Cited by 60
“Finally, dose-limiting toxicities—especially high-grade (grade 3/4) treatment-related adverse events—further complicate dose management and treatment continuation [72].”
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18
“In prostate cancer, PSMA is the most frequently targeted TAA due to its abundant expression on malignant cells, but other targets are currently being explored as well [26].”
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
Zhou, X., Hu, S., & Wang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101599 · Cited by 24
Khorasanchi, A., Hong, F., Yang, Y., Singer, E. A., Wang, P., Li, M., Zheng, L., Monk, P., Mortazavi, A., & Meng, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.173 · Cited by 39
Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives
Rai, V. (2025) · Biomolecules · doi:10.3390/biom15060751 · Cited by 18
Metadata
- Authors
- Lampe, H., Tam, L., & Hansen, A. R.
- Affiliations
- Queensland Health (AU)
- Corresponding author
- Hansen, Aaron R.
- ORCID
- Hansen, Aaron R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-05-30
- Volume
- 15
- Pages
- 1399802-1399802
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC11169794
- OpenAlex
- W4399178517
- Cited by
- 21
- References
- 100
- Citations by year
- 2026: 6 · 2025: 15
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- bispecific T-cell engagers, metastatic castration-resistant prostate cancer, immunotherapy, tumor microenvironment, anti-drug antibodies, treatment-related adverse events, treatment resistance, tumor-associated antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.